Table III.

Final Estimate of CYP2C19 CR to the Apparent Oral Clearance of Various Substrate Drugs

Drug	CRa	90% CIb
Mephobarbital R	0.99	0.99–1.0
Proguanil	0.89	0.87–0.90
Lansoprazole S	0.87	0.85–0.88
Omeprazole	0.84	0.82–0.86
Diazepam	0.84	0.81–0.86
Pantoprazole	0.80	0.76–0.83
Gliclazide	0.76	0.71–0.80
Lansoprazole R	0.74	0.68–0.79
Lansoprazole	0.73	0.67–0.78
Rabeprazole	0.72	0.65–0.77
Moclobemide	0.71	0.64–0.77
Sibutramine	0.69	0.61–0.75
Voriconazole	0.68	0.60–0.74
Sertraline	0.67	0.59–0.74
Clopidogrel	0.65	0.55–0.72
Fluoxetine	0.64	0.55–0.72
Citalopram	0.49	0.37–0.60
Trimipramine	0.49	0.36–0.60
Nelfinavir	0.46	0.33–0.58
Clomipramine	0.42	0.30–0.55
Escitalopram	0.45	0.33–0.57
Cilostazol	0.30	0.19–0.42
Amitriptyline	0.28	0.18–0.40
Nelfinavir a.f.	0.26	0.16–0.37
Praziquantel	0.18	0.10–0.27

CR contribution ratio, CI confidence interval

^aCR was calculated as the mean of the Bayesian posterior distribution

^bCI was calculated as the range between the 5th and the 95th percentiles of the Bayesian posterior distribution